Real Brands, Inc. Enters into Medical Psychedelics Market
March 24, 2022 at 08:01 am EDT
Share
Real Brands Inc. announced initiating expansion to become a premier provider of medical psychedelics. As Phase 1 of laying the groundwork for entry into the medical psychedelics market, Real Brands has entered a partnership with consulting firm Marcu & Arora to apply for U.S. Drug Enforcement Agency (DEA) licensure for psychedelics, including defining the protocols for application and the focus of the formulation research and development. Additionally, Real Brands will apply to the DEA for authorization to process and handle psychedelic substances, and it has applied to the state of Rhode Island to be able to prescribe, dispense, store and ship controlled substances.
Real Brands, Inc. is engaged in the business of hemp and cannabis industry. The Companyâs primary business is hemp cannabinoids (CBD) oil/isolate extraction, wholesaling of CBD oils and isolate, and manufacturing, production and sales of hemp-derived CBD consumer brands and white label products. It is extracting and refining oils and compounds of interest from hemp cultivars using its processing technology and methodology. Its products consist of oils, tinctures, capsules, topicals, edibles, and pet products. The Company acquires and/or develops brands that CBD and minor cannabinoids are complementary ingredients, and which are conducive to hemp derived infusion or micro encapsulation that is chocolates, cosmetics, edibles, drinks, sprays, tinctures, sub-lingual strips, cooking condiments, powders, vapes, and others. The Companyâs HALO.5 simulated moving bed chromatography system (SMB) is an integrated six-column SMB system designed for isolation and purification of chemical compounds.